Alkermes spin out Civitas reports CVT-301 data

Civitas Therapeutics Inc. (Chelsea, Mass.) said a single 50 mg dose of CVT-301 as an adjunct to standard oral medication met the primary endpoint of improving motor function vs. placebo in the Phase IIa CVT-301-002 trial to treat motor fluctuations associated with Parkinson's disease (PD). The single 25 mg dose of CVT-301 missed the endpoint. The double-blind, crossover trial enrolled 24 PD patients experiencing motor fluctuations to receive CVT-301, placebo or open-label Sinemet levodopa/carbidopa from Bristol-Myers Squibb Co. (NYSE:BMY) administered in the "off" state in which patients experienced symptoms of their PD. ...